Acorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc.; Encourages Investors to Contact the Firm

SAN DIEGO, Aug. 30, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP (J&W) is investigating potential violations of the federal securities laws by Acorda Therapeutics, Inc. ACOR ("Acorda") and certain of its officers. Acorda identifies, develops, and commercializes therapies for neurological disorders in the United States.

On August 29, 2017, Acorda disclosed that it had received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding the new drug application it had submitted in June for Inbrija, a potential treatment for Parkinson's disease. Acorda stated, "FDA specified two reasons for the RTF: first, the date when the manufacturing site would be ready for inspection, and, second, a question regarding the submission of the drug master production record."

If you have information that could assist in this investigation, including past employees and others, or if you are an Acorda shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by email or phone at 619-814-4471. If emailing, please include a phone number.

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com

View original content:http://www.prnewswire.com/news-releases/acorda-therapeutics-acor-alert--shareholder-rights-law-firm-jw-investigates-acorda-therapeutics-inc-encourages-investors-to-contact-the-firm-300511488.html

SOURCE Johnson & Weaver, LLP